HalioDx SAS. (4/19/19). "Press Release: HalioDx Signs an Exclusive Agreement with Genecast to Make Immunoscore Available in China". Marseille.

	Region	China
	Organisation	HalioDx SAS
	Organisation 2	Genecast (CN)
	Product	Immunoscore® Colon assay
	Product 2	pharmacodiagnostic test (PDx)
	Index term	Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast
	Person	Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO)
	Person 2	Du, Bo (Genecast (CN) 201904 CEO + Founder)

HalioDx SAS, an immuno-oncology company pioneeringhe immunological diagnosis of cancers, today announced that it has signed an exclusive distribution agreement with Genecast for Immunoscore® commercialization in China. Oncologists and patients in China will have access to Immunoscore®, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer.

Immunoscore® is an assay which combines tissue diagnostic and advanced image analysis technologies enabling extraction of spatially-organized tissue molecular informationto quantify lymphocytes which infiltrate both the core of the tumor and its invasive margin. The assay is quantitative and guides oncologists to decide on critical therapeutic options in stages II and stage III colon cancers1. It is the very first IVD assay of the HalioDx pipeline, leveraging image analysis technology to enhance clinical utility and standardization.

The clinical value of Immunoscore® has been validated in several studies on early stage colon cancer patients. The results of the SITC International study1conducted on more than 2600 patients have been published in The Lancet journal in 2018. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147study2.

“There are more than 500,000 new cases of colorectal cancers per year in China3 which represent a significant challenge for health organizationsin the country. For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore®, relapse risk assessment will be improved for early stage colon cancerpatients,” says Vincent Fert, CEO of HalioDx. He added “We are delighted to have signed this agreement with Genecast who have a proven record of success in the highly competitive cancer diagnostics market.”

“We are very pleased to partner with HalioDx. HalioDx’s choice to work with Genecast shows its high recognition of our comprehensive strengths and marketing ability in the Chinese market.” Mr. Bo Du, founder and CEO of Genecast, said, “Immunoscore® is a paragon of precision medicine in clinical practice. We highly recognize its values, and we are very pleased to be able to promote it in China so that the Chinese patients can receive better healthcare solutions.”

***

1 Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391 (10135)

2 Sinicrope F, Shi Q, Hermitte F et al. Immunoscore to provide prognostic information in low-(T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). J Clin Oncol. 2018; 36:4s (suppl; abstr 614)

3 International Agency for Research on Cancer, Globocan 2018

About HalioDx
The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis, enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

HalioDx has an experienced team of more than 135 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.haliodx.com and www.immunoscore-colon.comand follow the company on Twitter @HalioDx.

Contacts

HalioDx SAS
Vincent Fert
President and CEO
+ 33 (0)4 91 29 30 90
vincent.fert@haliodx.com

ATCG Press
Marie Puvieux/Solène Moulin (France)
+33 (0)9 81 87 46 72
Céline Voisin (ROW)
Mob: +33 (0)6 62 12 53 39
haliodx@atcg-partners.com

Twitter: twitter.com/haliodx

Record changed: 2024-03-30